Adrenal responses to low dose synthetic ACTH (Synacthen) in children receiving high dose inhaled fluticasone. Arch Dis Child

Division of Developmental Medicine, University of Glasgow, Royal Hospital for Sick Children, Glasgow G3 8SJ, Scotland, UK.
Archives of Disease in Childhood (Impact Factor: 2.9). 10/2006; 91(10):808-13. DOI: 10.1136/adc.2005.087247
Source: PubMed


Clinical adrenal insufficiency has been reported with doses of inhaled fluticasone proprionate (FP) > 400 microg/day, the maximum dose licensed for use in children with asthma. Following two cases of serious adrenal insufficiency (one fatal) attributed to FP, adrenal function was evaluated in children receiving FP outwith the licensed dose.
Children recorded as prescribed FP > or = 500 microg/day were invited to attend for assessment. Adrenal function was measured using the low dose Synacthen test (500 ng/1.73 m2 intravenously) and was categorised as: biochemically normal (peak cortisol response > 500 nmol/l); impaired (peak cortisol < or = 500 nmol/l); or flat (peak cortisol < or = 500 nmol/l with increment of < 200 nmol/l and basal morning cortisol < 200 nmol/l).
A total of 422 children had been receiving FP alone or in combination with salmeterol; 202 were not investigated (137 FP within license; 24 FP discontinued); 220 attended and 217 (age 2.6-19.3 years) were successfully tested. Of 194 receiving FP > or = 500 microg/day, six had flat responses, 82 impaired responses, 104 were normal, and in 2 the LDST was unsuccessful. Apart from the index child, the other five with flat responses were asymptomatic; a further child with impairment (peak cortisol 296 nmol/l) had encephalopathic symptoms with borderline hypoglycaemia during an intercurrent illness. The six with flat responses and the symptomatic child were all receiving FP doses of > or = 1000 microg/day.
Overall, flat adrenal responses in association with FP occurred in 2.8% of children tested, all receiving > or = 1000 microg/day, while impaired responses were seen in 39.6%. Children on above licence FP doses should have adrenal function monitoring as well as a written plan for emergency steroid replacement.

Download full-text


Available from: James Paton,
  • Source
    • "No of cases Symptoms and signs Triggering cause of adrenal crisis Duration of glucocorticoid therapy Glucocorticoid dose Confirmation of adrenal crisis Reference 1 Severe weakness, dizziness, nauseated and shaking No known stressors 24 months Prednisone 20 mg/d tapered and discontinued 2 weeks before Basal cortisol = 0 nmol/L Krasner 1999 [22] 33 (1 fatal) Hypoglycaemia (n = 23), decreased level of consciousness or coma (n = 13), vomiting (n = 2), insidious onset of symptoms (n = 5) Sepsis (fatal case), surgery (1 case), infections, exacerbation of asthma, reduction or discontinuation of ICS >3 years: 5 patients 1–2 years: 14 patients b1 year: 6 patients Inhaled glucocorticoids (91% fluticasone) 500–2000 μg/day and b 21 days with oral glucocorticoids in previous year (one patient more) Synacthen® test (n = 30) and/or low basal cortisol Todd et al. 2002 [11] 1 Hypoglycaemia, seizures Influenza vaccine Long-term (only 32 months old child) Inhaled fluticasone 440–1320 μg/day Synacthen® test Kennedy et al. 2002 [67] 1 Unconscious, unresponsive to stimulation, cyanosed, hypothermic, cushingoid features, hypoglycemia, seizure Respiratory infection 14 months Inhaled budesonide 1 mg × 4 Synacthen® test Dunlop et al. 2002 [68] 3 (with 1–3 episodes) Vomiting, abdominal pain, lethargy, hypoglycemia, hyponatremia Intercurrent illness Long-term Inhaled fluticasone 500–1500 μg/day Synacthen® test Macdessi et al. 2003 [69] 3 Weakness, malaise, fever, gastrointestinal symptoms, hypotension Sepsis (A + C), Infection (B) 1 × 5 weeks (A + B), 1 × 5 + 1 + 3 weeks (C) + 9 days tapering (all) All: prednisolone 60 mg/m 2 /day, A: tapered and discontinued 4 1/2 months before crisis, C: last 3 weeks dexamethasone 10 mg/m 2 /day Synacthen® test Rix et al. 2005 [31] 1 Tiredness, poor weight gain, mild encephalopathy, hypoglycemia Tonsillitis Not reported Inhaled fluticasone 1000 μg/day (no oral glucocorticoids) Synacthen® test Paton et al. 2006 [70] "
    [Show abstract] [Hide abstract]
    ABSTRACT: Glucocorticoid therapy is widely used, but withdrawal from glucocorticoids comes with a potential life-threatening risk of adrenal insufficiency. Recent case reports document that adrenal crisis after glucocorticoid withdrawal remains a serious problem in clinical practice. Partly due to difficulties in inter-study comparison the true prevalence of glucocorticoid-induced adrenal insufficiency is unknown, but it might be somewhere between 46 and 100% 24h after glucocorticoid withdrawal, 26-49% after approximately one week, and some patients show prolonged suppression lasting months to years. Adrenal insufficiency might therefore be underdiagnosed in clinical practice. Clinical data do not permit accurate estimates of a lower limit of glucocorticoid dose and duration of treatment, where adrenal insufficiency will not occur. Due to individual variation, neither the glucocorticoid dose nor the duration of treatment can be used reliably to predict adrenal function after glucocorticoid withdrawal. Also the recovery rate of the adrenal glands shows individual variation, which may be why there is currently insufficient evidence to prove the efficacy and safety of different withdrawal regimens. Whether a patient with an insufficient response to an adrenal stimulating test develops clinically significant adrenal insufficiency depends on the presence of stress and resulting glucocorticoid demand and it is thus totally unpredictable and can change relative fast. Adrenal insufficiency should therefore always be taken seriously. Individual variation in hypothalamic-pituitary-adrenal axis function might be due to differences in glucocorticoid sensitivity and might be genetic. Further awareness of the potential side effect of withdrawal of glucocorticoid and further research are urgently needed.
    European Journal of Internal Medicine 06/2013; 25(8). DOI:10.1016/j.ejim.2013.05.014 · 2.89 Impact Factor
  • Source
    • "It was demonstrated that age, being a normal volunteer inhaler technique and compliance, plays a role in determining the systemic effects of ICS. In spite of this, Paton J et al. reported that clinical adrenal insufficiency was particularly associated with high doses (> 400 μg/day) of inhaled FP in children with asthma [4]. Wilson AM et al. demonstrated that high doses of inhaled FP alone were associated with adrenal suppression and CS features with use over 2 years in a female asthmatic patient. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Current guidelines recommend the use of inhaled corticosteroids (ICS) for suppression of airway inflammation in patients with asthma. Although it is well known that ICS cause dose-related adrenocortical suppression, it is less known that they can lead to iatrogenic Cushing's syndrome (CS). Fluticasone propionate (FP) is an ICS more potent than beclomethasone and budesonide. FP is metabolized as mediated by cytochrome P450 3A4 in the liver and the gut. Systemic bioactivity of FP can increase with the use of drugs that affect the cytochrome P450. Herein, we report the rapid development of iatrogenic CS in a patient receiving paroxetine and mirtazepine for 12 weeks in addition to inhaled FP.
    08/2012; 7(1):26. DOI:10.1186/2049-6958-7-26
  • Source
    • "Twelve weeks after the switch, abnormal low-dose ACTH test results indicative of AS were noted in over 60% of patients in each treatment group [74]. Paton et al. used the low-dose ACTH stimulation test to assess adrenal function in 194 children receiving ≥500 μg/day of fluticasone and found that approximately 40% of these subjects had evidence of AS [18]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Inhaled corticosteroids (ICSs) are the most effective anti-inflammatory agents available for the treatment of asthma and represent the mainstay of therapy for most patients with the disease. Although these medications are considered safe at low-to-moderate doses, safety concerns with prolonged use of high ICS doses remain; among these concerns is the risk of adrenal suppression (AS). AS is a condition characterized by the inability to produce adequate amounts of the glucocorticoid, cortisol, which is critical during periods of physiological stress. It is a proven, yet under-recognized, complication of most forms of glucocorticoid therapy that can persist for up to 1 year after cessation of corticosteroid treatment. If left unnoticed, AS can lead to significant morbidity and even mortality. More than 60 recent cases of AS have been described in the literature and almost all cases have involved children being treated with ≥500 μg/day of fluticasone. The risk for AS can be minimized through increased awareness and early recognition of at-risk patients, regular patient follow-up to ensure that the lowest effective ICS doses are being utilized to control asthma symptoms, and by choosing an ICS medication with minimal adrenal effects. Screening for AS should be considered in any child with symptoms of AS, children using high ICS doses, or those with a history of prolonged oral corticosteroid use. Cases of AS should be managed in consultation with a pediatric endocrinologist whenever possible. In patients with proven AS, stress steroid dosing during times of illness or surgery is needed to simulate the protective endogenous elevations in cortisol levels that occur with physiological stress. This article provides an overview of current literature on AS as well as practical recommendations for the prevention, screening and management of this serious complication of ICS therapy.
    Allergy Asthma and Clinical Immunology 08/2011; 7(1):13. DOI:10.1186/1710-1492-7-13 · 2.03 Impact Factor
Show more